UniProt ID | SIN1_HUMAN | |
---|---|---|
UniProt AC | Q9BPZ7 | |
Protein Name | Target of rapamycin complex 2 subunit MAPKAP1 | |
Gene Name | MAPKAP1 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 522 | |
Subcellular Localization |
Cell membrane Peripheral membrane protein. Cytoplasmic vesicle. Nucleus. |
|
Protein Description | Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals. mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. Within mTORC2, MAPKAP1 is required for complex formation and mTORC2 kinase activity. MAPKAP1 inhibits MAP3K2 by preventing its dimerization and autophosphorylation. Inhibits HRAS and KRAS signaling. Enhances osmotic stress-induced phosphorylation of ATF2 and ATF2-mediated transcription. Involved in ciliogenesis, regulates cilia length through its interaction with CCDC28B independently of mTORC2 complex.. | |
Protein Sequence | MAFLDNPTIILAHIRQSHVTSDDTGMCEMVLIDHDVDLEKIHPPSMPGDSGSEIQGSNGETQGYVYAQSVDITSSWDFGIRRRSNTAQRLERLRKERQNQIKCKNIQWKERNSKQSAQELKSLFEKKSLKEKPPISGKQSILSVRLEQCPLQLNNPFNEYSKFDGKGHVGTTATKKIDVYLPLHSSQDRLLPMTVVTMASARVQDLIGLICWQYTSEGREPKLNDNVSAYCLHIAEDDGEVDTDFPPLDSNEPIHKFGFSTLALVEKYSSPGLTSKESLFVRINAAHGFSLIQVDNTKVTMKEILLKAVKRRKGSQKVSGPQYRLEKQSEPNVAVDLDSTLESQSAWEFCLVRENSSRADGVFEEDSQIDIATVQDMLSSHHYKSFKVSMIHRLRFTTDVQLGISGDKVEIDPVTNQKASTKFWIKQKPISIDSDLLCACDLAEEKSPSHAIFKLTYLSNHDYKHLYFESDAATVNEIVLKVNYILESRASTARADYFAQKQRKLNRRTSFSFQKEKKSGQQ | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MAFLDNPTI ------CCCCCCCEE | 17.45 | - | |
84 | Phosphorylation | DFGIRRRSNTAQRLE HHCCCCCCCHHHHHH | 36.40 | 22817900 | |
86 | Phosphorylation | GIRRRSNTAQRLERL CCCCCCCHHHHHHHH | 25.97 | 22817900 | |
113 | O-linked_Glycosylation | IQWKERNSKQSAQEL CCHHHHCCHHHHHHH | 37.99 | 30379171 | |
116 | O-linked_Glycosylation | KERNSKQSAQELKSL HHHCCHHHHHHHHHH | 35.34 | 30379171 | |
121 | Ubiquitination | KQSAQELKSLFEKKS HHHHHHHHHHHHHHC | 44.34 | - | |
128 | Phosphorylation | KSLFEKKSLKEKPPI HHHHHHHCCCCCCCC | 56.60 | - | |
140 | Phosphorylation | PPISGKQSILSVRLE CCCCCCCEEEEEEEE | 29.05 | 20873877 | |
143 | Phosphorylation | SGKQSILSVRLEQCP CCCCEEEEEEEECCC | 11.97 | 20873877 | |
160 | Phosphorylation | LNNPFNEYSKFDGKG CCCCCCCCCCCCCCC | 20.47 | 23090842 | |
161 | Phosphorylation | NNPFNEYSKFDGKGH CCCCCCCCCCCCCCC | 22.22 | 23090842 | |
162 | Ubiquitination | NPFNEYSKFDGKGHV CCCCCCCCCCCCCCC | 46.72 | - | |
166 | Ubiquitination | EYSKFDGKGHVGTTA CCCCCCCCCCCCCCC | 47.92 | - | |
180 | Phosphorylation | ATKKIDVYLPLHSSQ CCCEEEEEEECCCCC | 10.00 | 23403867 | |
185 | Phosphorylation | DVYLPLHSSQDRLLP EEEEECCCCCCCCCC | 37.06 | 23911959 | |
186 | Phosphorylation | VYLPLHSSQDRLLPM EEEECCCCCCCCCCC | 25.92 | 23911959 | |
194 | Phosphorylation | QDRLLPMTVVTMASA CCCCCCCCHHHHHHH | 15.19 | 24043423 | |
197 | Phosphorylation | LLPMTVVTMASARVQ CCCCCHHHHHHHHHH | 11.59 | 24043423 | |
200 | Phosphorylation | MTVVTMASARVQDLI CCHHHHHHHHHHHHH | 13.04 | 24043423 | |
214 | Phosphorylation | IGLICWQYTSEGREP HHHHHEEECCCCCCC | 6.42 | 24043423 | |
215 | Phosphorylation | GLICWQYTSEGREPK HHHHEEECCCCCCCC | 12.76 | 24043423 | |
216 | Phosphorylation | LICWQYTSEGREPKL HHHEEECCCCCCCCC | 32.87 | 24043423 | |
260 | Phosphorylation | PIHKFGFSTLALVEK CHHHCCCCHHHHHHH | 23.92 | 28857561 | |
261 | Phosphorylation | IHKFGFSTLALVEKY HHHCCCCHHHHHHHC | 17.49 | 28270605 | |
268 | Phosphorylation | TLALVEKYSSPGLTS HHHHHHHCCCCCCCC | 10.81 | 28270605 | |
269 | Phosphorylation | LALVEKYSSPGLTSK HHHHHHCCCCCCCCC | 40.92 | 26657352 | |
270 | Phosphorylation | ALVEKYSSPGLTSKE HHHHHCCCCCCCCCC | 21.64 | 25159151 | |
274 | Phosphorylation | KYSSPGLTSKESLFV HCCCCCCCCCCEEEE | 43.60 | 28270605 | |
275 | Phosphorylation | YSSPGLTSKESLFVR CCCCCCCCCCEEEEE | 39.20 | 28270605 | |
276 | Ubiquitination | SSPGLTSKESLFVRI CCCCCCCCCEEEEEE | 46.19 | - | |
302 | Ubiquitination | DNTKVTMKEILLKAV CCCEEEHHHHHHHHH | 32.03 | - | |
315 | Phosphorylation | AVKRRKGSQKVSGPQ HHHHCCCCCCCCCCC | 29.84 | 23312004 | |
319 | Phosphorylation | RKGSQKVSGPQYRLE CCCCCCCCCCCHHCC | 52.36 | 23401153 | |
323 | Phosphorylation | QKVSGPQYRLEKQSE CCCCCCCHHCCCCCC | 21.94 | 23312004 | |
367 | Phosphorylation | DGVFEEDSQIDIATV CCCCCCCCCCEEEHH | 32.11 | 28348404 | |
428 | Ubiquitination | TKFWIKQKPISIDSD CEEEECCCCCCCCHH | 39.04 | - | |
447 | Phosphorylation | CDLAEEKSPSHAIFK HHHCCCCCCCCCEEE | 34.61 | 25159151 | |
449 | Phosphorylation | LAEEKSPSHAIFKLT HCCCCCCCCCEEEEE | 32.42 | 25159151 | |
456 | Phosphorylation | SHAIFKLTYLSNHDY CCCEEEEEEECCCCC | 24.02 | 25954137 | |
457 | Phosphorylation | HAIFKLTYLSNHDYK CCEEEEEEECCCCCC | 20.69 | 25954137 | |
459 | Phosphorylation | IFKLTYLSNHDYKHL EEEEEEECCCCCCEE | 23.00 | 25159151 | |
463 | Phosphorylation | TYLSNHDYKHLYFES EEECCCCCCEEEEEC | 7.86 | 25954137 | |
467 | Phosphorylation | NHDYKHLYFESDAAT CCCCCEEEEECCCCC | 12.67 | 25954137 | |
470 | Phosphorylation | YKHLYFESDAATVNE CCEEEEECCCCCHHH | 23.73 | 25954137 | |
497 | Phosphorylation | ASTARADYFAQKQRK HCHHHHHHHHHHHHH | 10.38 | - | |
501 | Ubiquitination | RADYFAQKQRKLNRR HHHHHHHHHHHHHCC | 48.95 | - | |
509 | Phosphorylation | QRKLNRRTSFSFQKE HHHHHCCCCCCCCHH | 30.77 | 30266825 | |
510 | Phosphorylation | RKLNRRTSFSFQKEK HHHHCCCCCCCCHHH | 19.65 | 29255136 | |
512 | Phosphorylation | LNRRTSFSFQKEKKS HHCCCCCCCCHHHHC | 26.91 | 30266825 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of SIN1_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of SIN1_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-510, AND MASSSPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-510, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-270 AND SER-510, ANDMASS SPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-510, AND MASSSPECTROMETRY. |